Breakthrough Chemistry, Inc. (OTCPK: BKTH)
Health Care · Pharmaceuticals · US
$0.21
+11.98% today · +16.3% 1Y
Breakthrough Chemistry, Inc. (OTCPK: BKTH) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.02M and employs 3 people.
Over the last twelve months the share price has gained 16.3%, trading between 0.03 and 0.35.
Tweenvest scores Breakthrough Chemistry, Inc. across four factors: quality 23/100, value 51/100. Its strongest factor is value.
BKTH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.02M
- Revenue (TTM)
- $19.18K
- P/E
- —
- EPS
- -0.02
- Dividend yield
- —
- Beta (5Y)
- 5.08
- 52-week high
- $0.35
- 52-week low
- $0.03
- Avg volume (3M)
- —
- Shares outstanding
- 9.73M
- Employees
- 3
- Next earnings
- —
About Breakthrough Chemistry, Inc.
Breakthrough Chemistry, Inc. is an innovator in the chemical sector, engineering novel compounds and formulations that challenge established industry standards. Leveraging its advanced chemistry platform, the company provides critical solutions across a diverse range of areas. These include enhancing food security and minimizing spoilage, promoting natural resource conservation, improving personal hygiene, crafting protective surface coatings, eliminating unwanted odors, and facilitating chemical neutralization. Based in Bonita Springs, Florida, the organization underwent a rebranding in July 2025, transitioning from its former identity as Megola, Inc. to its current name, Breakthrough Chemistry, Inc.
- ISIN
- US58517C4042
- Listed since
- Dec 12, 2002
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.